NCT06405217View on ClinicalTrials.gov

Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
DTC - Differentiated Thyroid CancerThyroid Stimulating; Hormone, CRadiotherapy; Complications
Interventions
DRUG

Recombinant Human Thyroid Stimulating Hormone

Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days

Trial Locations (1)

210006

RECRUITING

Nanjing First Hospital, Nanjing

All Listed Sponsors
lead

Nanjing First Hospital, Nanjing Medical University

OTHER